Roche plans to launch a Phase 2 trial combining petrelintide and enicepatide, positioning the company to test whether its two obesity injectables can deliver differentiated efficacy with an acceptable tolerability profile. The plan follows Roche’s outreach at ADA26 emphasizing petrelintide as a potential best-in-class safety option and enicepatide as a complementary efficacy bet. Roche’s stated intent to initiate the combination study later this year underscores the industry’s move from single-agent obesity programs toward combination strategies designed to overcome plateauing and improve outcome depth across broader patient groups.